Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations (NCT06581432)
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours
🩺 Plain-English Summary (8th-Grade Level)
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology and Hematology, LLC — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (89 Sites)
Showing the first 25 of 89 sites.
- Alaska Oncology and Hematology, LLC — Anchorage, Alaska
- University of Arizona Comprehensive Cancer Center — Tucson, Arizona
- Precision NextGen Oncology — Beverly Hills, California
- Scripps Cancer Center Torrey Pines — La Jolla, California
- Valkyrie Clinical Trials — Los Angeles, California
- Yale University School of Medicine — New Haven, Connecticut
- BRCR Global — Tamarac, Florida
- Illinois Cancer Specialists — Arlington Heights, Illinois
- Community MD Anderson Cancer Center - East Medical Oncology — Indianapolis, Indiana
- Maryland Oncology Hematology, Columbia — Columbia, Maryland
- Karmanos Cancer Institute — Detroit, Michigan
- Presbyterian Healthcare Services — Albuquerque, New Mexico
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Taylor Cancer Research Center — Maumee, Ohio
- Alliance Cancer Specialists, PC, Wynnewood — Wynnewood, Pennsylvania
- Sarah Cannon Research Institute at Mary Crowley — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - Plano West — Plano, Texas
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Macquarie University — Macquarie Park, New South Wales
- GenesisCare North Shore — St Leonards, New South Wales
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Cancer Research South Australia — Adelaide, South Australia
- St John of God Subiaco Hospital — Subiaco, Western Australia
📞 Contact the Study Coordinator
Phone: (800) 243-0127
Email: clintriage.rdg@boehringer-ingelheim.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumours
- A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Beverly Hills, California
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours — New York, New York
- A Study of BI 3810944 in Patients With Advanced Cancer — Louisville, Kentucky
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Irvine, California
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — Beverly Hills, California
Explore by condition: All Solid Tumours clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.